Please check your internet connection and try again.
# Genixim (Cefixime)
## Overview
Genixim is a third-generation cephalosporin antibiotic. It acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). It is stable against many beta-lactamases and provides expanded Gram-negative coverage compared to first/second-generation cephalosporins, but has limited activity against Gram-positive organisms (e.g., *Staphylococcus aureus*).
## Primary Indications
* Uncomplicated urinary tract infections (UTIs)
* Otitis media
* Pharyngitis and tonsillitis
* Uncomplicated gonorrhea (cervical, urethral, and rectal)
* Acute exacerbations of chronic bronchitis
## Adult Dosing
* **General infections:** 400 mg daily, administered as a single dose or in two divided doses of 200 mg every 12 hours.
* **Uncomplicated gonorrhea:** 800 mg orally as a single dose (often in combination with doxycycline if *Chlamydia* is not ruled out).
## Pediatric Dosing
* **Children ≥ 6 months:** 8 mg/kg/day, administered once daily or in two divided doses of 4 mg/kg every 12 hours.
* **Max Pediatric Dose:** 400 mg daily.
## Dose Adjustments
* **Renal Impairment:**
* CrCl 21–60 mL/min: Reduce dose to 75% of the standard dose.
* CrCl < 20 mL/min: Reduce dose to 50% of the standard dose.
* **Hemodialysis:** No supplementary dose is required post-dialysis as it is not significantly removed.
## Contraindications
* Known hypersensitivity to cefixime or other cephalosporins.
* History of severe allergic reactions (e.g., anaphylaxis) to penicillins or other beta-lactams.
## Adverse Effects
* **Common:** Diarrhea (most frequent), nausea, abdominal pain, dyspepsia.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (rash, urticaria, serum sickness), and rare cases of Stevens-Johnson syndrome or toxic epidermal necrolysis.
## Key Drug Interactions
* **Anticoagulants:** May increase the effect of warfarin; monitor INR.
* **Probenecid:** May increase serum concentrations and half-life of cefixime by inhibiting renal excretion.
* **Vaccines:** May decrease the efficacy of the BCG vaccine or the typhoid vaccine.
## Monitoring
* Monitor for signs of hypersensitivity.
* If treatment is prolonged, monitor renal and hepatic function.
* Assess for persistent diarrhea to rule out *C. difficile* infection.
## Clinical Pearls
* **Bioavailability:** Cefixime oral suspension has higher bioavailability than the tablet form; they are not strictly bioequivalent if switching between formulations.
* **Spectrum:** It has poor activity against *Pseudomonas aeruginosa* and methicillin-resistant *Staphylococcus aureus* (MRSA), and should not be used as empiric therapy for these pathogens.
* **Administration:** It can be taken with or without food.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines vary by region and institution. Always verify specific dosing, safety precautions, and interactions using the most recent official prescribing information or your institution’s antimicrobial stewardship protocols before prescribing or administering medication.
